Nestle, the massive Swiss food company, announced on Tuesday that it will be introducing items in the US for consumers of the growingly popular weight-loss medications.
Those who use GLP-1 weight reduction medicine to control type 2 diabetes and obesity are the target market for the new Vital Pursuit brand, according to Nestle, the company behind KitKat chocolate and Nespresso coffee pods.
Nestle noted in a statement that the new range, which includes pizza, pasta, and sandwiches at suggested prices of $4.99 or less, will provide users of weight reduction medications with nutrient-dense, protein- and fiber-rich cuisine.
The items, according to the firm, would help satisfy dietary requirements with portion sizes tailored to wane as people continue their therapy. They are expected to hit US markets in the final three months of 2024.
One in sixty adults were prescribed a GLP-1 medicine in 2023, according to the American Pharmacists Association, and Nestle predicted that number will increase this year.
The medications mimic a hormone released by the human intestines, which in turn triggers the production of insulin and suppresses hunger by creating a sensation of fullness.
Due to its slimming qualities, well-known brands like Ozempic and Wegovy have become so popular on social media that some of their supply has gone out.
The financial world is questioning the growth potential of confectionary manufacturers whose goods contain high levels of fat, sugar, and salt because to the enthusiasm for such treatments.
During the April general meeting, Nestle faced harsh criticism from certain investors who insisted the company set higher standards for the percentage of nutritious goods it sold.
